- Home
- DHAI vs FBIO Comparison
DHAI vs FBIO Comparison
Compare DHAI & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- FBIO
- Stock Information
- Founded
- DHAI 2007
- FBIO 2006
- Country
- DHAI United States
- FBIO United States
- Employees
- DHAI N/A
- FBIO N/A
- Industry
- DHAI
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- DHAI
- FBIO Health Care
- Exchange
- DHAI NYSE
- FBIO Nasdaq
- Market Cap
- DHAI 49.1M
- FBIO 39.4M
- IPO Year
- DHAI N/A
- FBIO N/A
- Fundamental
- Price
- DHAI $1.23
- FBIO $1.87
- Analyst Decision
- DHAI
- FBIO Strong Buy
- Analyst Count
- DHAI 0
- FBIO 3
- Target Price
- DHAI N/A
- FBIO $18.00
- AVG Volume (30 Days)
- DHAI 430.9K
- FBIO 658.0K
- Earning Date
- DHAI 11-14-2024
- FBIO 11-14-2024
- Dividend Yield
- DHAI N/A
- FBIO N/A
- EPS Growth
- DHAI N/A
- FBIO N/A
- EPS
- DHAI N/A
- FBIO N/A
- Revenue
- DHAI $73,490,000.00
- FBIO $81,501,000.00
- Revenue This Year
- DHAI N/A
- FBIO N/A
- Revenue Next Year
- DHAI N/A
- FBIO $128.63
- P/E Ratio
- DHAI N/A
- FBIO N/A
- Revenue Growth
- DHAI 16.95
- FBIO 31.51
- 52 Week Low
- DHAI $0.72
- FBIO $1.36
- 52 Week High
- DHAI $3.67
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- DHAI 45.76
- FBIO 44.79
- Support Level
- DHAI $1.22
- FBIO $1.84
- Resistance Level
- DHAI $1.57
- FBIO $2.36
- Average True Range (ATR)
- DHAI 0.33
- FBIO 0.18
- MACD
- DHAI -0.05
- FBIO -0.03
- Stochastic Oscillator
- DHAI 4.05
- FBIO 5.77
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.